2024; 22(4): 554-564  https://doi.org/10.9758/cpn.24.1179
Relationships between Gut Microbiota and Autism Spectrum Disorders: Development and Treatment
Lisa Poupard1, Guylène Page1,2, Vincent Thoreau1,2, Zahyra Kaouah1,2
1Medicine and Pharmacy Faculty, University of Poitiers, Poitiers, France
2Neurovascular Unit and Cognitive Disorders (NEUVACOD), Pôle Biologie Santé, University of Poitiers, Poitiers, France
Correspondence to: Lisa Poupard
Medicine and Pharmacy Faculty, University of Poitiers, 6 Rue de la Milétrie, Bât. D1, TSA 51115, 86073 POITIERS Cedex 9, France
E-mail: lisa.poupard@etu.univ-poitiers.fr
ORCID: https://orcid.org/0009-0001-2418-6669
Received: February 15, 2024; Revised: May 31, 2024; Accepted: June 3, 2024; Published online: July 25, 2024.
© The Korean College of Neuropsychopharmacology. All rights reserved.

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Many studies have demonstrated the impact of intestinal microbiota on normal brain development. Moreover, the gut microbiota (GM) is impacted by multiple endogenous and environmental factors that may promote gut dysbiosis (GD). An increasing number of studies are investigating the possible role of the GD in the development of neurological and behavioral disorders. For autism spectrum disorders (ASD), specific intestinal bacterial signatures have been identified, knowing that gastrointestinal symptoms are frequently found in ASD. In this review, the peri and post-natal factors modulating the GM are described and the specific gut bacterial signature of ASD children is detailed. Through bidirectional communication between the GM and the brain, several mechanisms are involved in the development of ASD, such as cytokine-mediated neuroinflammation and decreased production of neuroprotective factors such as short-chain fatty acids by the GM. Imbalance of certain neurotransmitters such as serotonin or gamma-aminobutyric acid could also play a role in these gut-brain interactions. Some studies show that this GD in ASD is partly reversible by treatment with pre- and probiotics, or fecal microbiota transplantation with promising results. However, certain limitations have been raised, in particular concerning the short duration of treatment, the small sample sizes and the diversity of protocols. The development of standardized therapeutics acting on GD in large cohort could rescue the gastrointestinal symptoms and behavioral impairments, as well as patient management.
Keywords: Autism spectrum disorders; Gastrointestinal microbiome; Neurodevelopment; Fecal microbiota transplantation
INTRODUCTION

Autism spectrum disorders (ASD) gather heterogeneous neurodevelopmental disorders, often diagnosed in childhood. ASD are psychiatric disorders described in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition [1]. The set of ASD disorders have some common neurocognitive symptoms as difficulties to have social and affective interactions, repetitive sensory-motor behaviors, and dysfunctions of perception and integration of information [2,3]. These disorders have a worldwide impact, but epidemiological data about ASD people are not very accurate [4]. On the one hand, the rate of ASD patients is increasing in developed countries, reaching up to 5% of the overall population. On the other hand, it is difficult to obtain accurate data in emerging countries. Moreover, there are few diagnoses of ASD in adulthood, which could explain an underestimation of ASD worldwide population [4,5]. Nevertheless, it is known that more men are diagnosed with ASD than women in the world [5]. Environmental factors such as food, prenatal and postnatal lifestyle, genetics, neurobiology, microbiota or gut dysbiosis (GD) could cause ASD [6,7]. GD is particularly interesting to study because it represents a common symptom of ASD. About 70% of children with ASD could suffer of gastro-intestinal symptoms (GIS), such as diarrhea, constipation, or abdominal pain. There seems to be a correlation between severity of GIS and neurological ASD symptoms [6,8,9]. The prevalence of GIS in ASD population is more important than in the general population [10,11]. Moreover GIS is still one of the most common symptom found in ASD population associated to GD [5,8]. The composition of gut microbiota (GM) could be a little different between individuals, but some specific phenotypes linked with ASD are established [12,13]. Bacterial signatures of the GM vary from one subject to another, but some bacterial genus are found and others disappear specifically in ASD [13]. GM could also be modified by many prenatal and postnatal factors as type of birth, breastfeeding, circadian rhythm, antibiotics, stress [7,14]. GM and brain have a bidirectional communication and constitute the microbiota-gut-brain-axis [12]. In fact, healthy GM has several essential roles in the organism, including producing essential nutrients for the brain (short-chain fatty acid or essential vitamins) and also some neurotransmitters as gamma-aminobutyric acid (GABA) or serotonin [7]. The communication between GM and brain is essential and impacts the physiological functions of the brain [15].

Most of what we know about the role of the GM in normal brain development comes from experiments carried out in mice treated with antibiotics, or in pregnant mice, either germ-free (GF mice) or reared in specific pathogen-free environment (SPF mice). Depletion of the maternal microbiome early to mid-gestation altered the expression of 333 genes in fetal brains of embryos at 14.5 days, including many involved in fetal thalamocortical axonogenesis and yields adult offspring with disrupted neurobehavioral responses to forepaw and hindpaw tactile stimuli [16]. Both in vivo and ex vivo magnetic resonance imaging revealed that SPF mice with commensal bacteria demonstrated several larger regions in grey matter and other brain regions than GF mice without commensal bacteria. This suggests that commensal bacteria are necessary for normal morphological development and maturation in the grey and white matter of the brain regions with implications for behavioral outcomes such as locomotion and cognitive functions [17]. Furthermore, a study revealed a role for the maternal microbiome in supporting placental growth and vascular development during pregnancy [18]. Placental vascular deficiencies characteristic of hypertensive disorders of pregnancy, and preeclampsia in particular, are associated with increased risk for myriad diseases in adulthood, including cardiovascular disease, kidney disease, and cognitive impairment [19]. In addition, authors showed that the offspring from viral-infected pregnant mice exhibits behavioral abnormalities including abnormal communication, increased repetitive behaviors, and deficits in sociability, and displays patches of disorganized cortical cytoarchitecture during embryonic development as well as in adulthood [20,21]. Similar cortical patches were observed in prefrontal and temporal cortical tissues of children with autism [22].

In this way, GD could have many impacts on the health and particularly on cerebral or neurological diseases [12]. Somes diseases are linked with modifications of microbiota, such as anxiety, depression, schizophrenia, Alzheimer’s disease (AD) and ASD [12].

In the context of neurodevelopmental disorder as ASD, GD have an impact on the brain development that could lead to behavioral alterations. It was demonstrated that the transfer of GM into germ-free mice could lead to extensive alternative splicing of gene involve in axonal growth, neuronal migration and synaptic communication in the offspring [23]. Another study demonstrated that transfer of GM from ASD children could induce an alteration in tryptophan and serotonin metabolism in germ-free mice [24]. These studies suggest that GM could lead to an alteration in brain development and functions in ASD context. The GD in neuropsychiatric disorders could be modified and partially reversible in different ways based on the microbiome, as fecal microbiota transplantation (FMT) [25], administration of prebiotics or probiotics. There is a link between reversibility of dysbiosis and decreasing of symptoms [26]. In AD patients, studies have shown a beneficial effect of FMT in cognitive impairments [27,28]. In ASD, there are human trials about prebiotics and probiotics, and about FMT [26]. Prebiotics and probiotics induce a reduction of GIS and cognitive impairments [26]. FMT has been administered to children in different trials, and the results look promising [6,29].

Firstly, the different gut bacterial signatures associated to ASD are described. Secondly, the microbiota mechanisms involved in the ASD are developed. The third part gathers the different therapeutic strategies based on the modulation of GM.

MAIN SUBJECTS

Comparison between Phenotypes of Gut Microbiota from Healthy and Autism Spectrum Disorders Children

Impact of gut microbiota by peri and post-natal factors

The GM begins to develop before birth and is modulated by many perinatal factors such as type of birth, diet or maternal GM. For example, an infection of the mother by filamentous bacteria during pregnancy can stimulate the mother’s immune system, and increase the production of interleukin 17 (IL-17). This cytokine can go through the placenta and impact the brain of the fetus (Fig. 1) [30]. Another study showed that maternal GM of mice could produce some metabolites such as imidazole propionate or 3-indoxyl sulfate, which could promote thalamic axogenesis in fetuses. Models of SPF mice or intestinal microbiota-depleted mice by antibiotic treatment have shown reduced thalamic axogenesis in their fetuses [16]. Moreover, some bacteria can cross the placenta, and colonize the fetal gut during pregnancy [31]. The intestinal microbiota is considered mature in human at 3 to 5-year-old [32]. Nevertheless, early modifications in GM can have an impact on the child’s future mental health. Using quantitative polymerase chain reaction (qPCR) analysis of bacterial genus found in the fecal microbiota of 1-month-old babies, a study showed significant differences in bacterial genera under the different conditions studied. Bacterial Actinobacteria and Bacteroides phyla were found in greater quantities in vaginally-born infants than in those born by caesarean section [32-34]. Firmicute phylum is more common in babies born by caesarean section [33]. Breastfeeding favors the presence of Firmicutes phylum and Bacteroides genus [32,33]. Exclusive breastfeeding helps to reduce the number of Enterococcus genus at 1 month. The decrease of Enterococcus is significant in babies born vaginally and with breastfeeding, compared to babies born vaginally and with mixed feeding (Fig. 1) [32]. Another study, which examined 16S rRNA in the meconium of newborn infants and in the stools of 1-month-old infants showed that the quantity of bacteria differed according to the conditions, but that the bacterial phyla found in both conditions remained identical [33]. An analysis compared the microbiota found at birth and after 1 month in different conditions, and showed significative changes such as a decrease in Proteobacteria phylum at 1 month, and an increase in the presence of Firmicutes [33]. The microbiota develops and evolves throughout life, but GD often appears in toddlers and elderly people [14]. Factors such as the use of antibiotics in children can reduce microbiota diversity and delay maturation [34,35]. A child taking azithromycin for 3 days reduces the diversity of the intestinal microbiota, notably impacting Proteobacteria. Macrolides administered for 6 months also have an impact on the microbiota, notably with a decrease in the Actinobacteria phylum [36]. Penicillin and other antibiotic classes also have an impact on the microbiota, sometimes even long term [35]. Other factors can modulate the microbiota, such as diet or circadian rhythm which can increase stress (Fig. 1) [7,37]. Indeed, stress can induce a decrease in rodent’s Lactobacillus population [37].

Specific gut bacterial signature of autism spectrum disorders children

The bacterial signatures of the GM in autistic children aged 2 to 4 years compared with non-autistic children appeared significantly different, in a study identifying bacterial phenotypes from stool. Moreover, 16S rRNA gene analysis identified 91 different operational taxonomic units (OTUs) in all children [38]. Other studies showed that some OTUs are found only in ASD children compared to control children [39]. In another study, 65 OTUs were found to be more abundant in ASD children, while 29 were found to be less abundant in ASD children than in control children [38]. However, the results of bacterial phylum and genus identification remain heterogeneous even in ASD children [38,40]. The Actinobacteria phylum appears to be less abundant in ASD children, particularly the Bifidobacterium genus [41,42]. The Coriobacteriaceae family is less abundant in ASD children too [41]. These two bacterial types normally constitute an important part of the child’s microbiota [39,41]. Bifidobacterium genus could play a protective psychobiotic role, help production of neurotransmitters that could have a positive influence on the gut-brain-axis. For example, it produces the amino acid tryptophan, which is a precursor of the neurotransmitter serotonin. Serotonin could promote functioning of serotoninergic neurons and help reduce anxiety and depression [38,43]. Bifidobacterium, and more specifically Bifidobacterium longum, could play a role to reduce the level of an inflammatory cytokine such as IL-6 in fetal enterocytes in vitro [40]. There is also an increase in Firmicutes and Bacteroidetes phyla in ASD children [38,39]. Firmicutes is normally the most abundant phylum in healthy subjects, but the increase of the phylum Bacteroidetes in ASD children causes an inversion of the Firmicutes/Bacteroidetes ratio (Fig. 1). All genera of the phylum Firmicutes are increased in ASD children, except Streptococci, that is found in lesser quantities than in control children [38]. The Proteobacteria phylum is also more abundant in ASD children, particularly the Enterobacteriaceae family. This bacterial family and other Gram-negative bacteria could be linked with higher level of lipopolysaccharides (LPS) in the serum of ASD patient, that could stimulate the production of inflammatory cytokine and a decrease in the social behavior score in ASD children [38]. Some genera are more common in ASD children than in control children, such as Streptococcus, Lactobacillus, Ruminococcus, Ruminoclostridium and Lactococcus [39]. Inversely, other genera, such as Flavonifractor and Acinetobacter, or some families such as Gemellaceae or Streptococcaceae were scarce in ASD group as in healthy children [38,39]. These differences in microbiota composition and abundance between children could have an impact on communication via the gut-brain-axis [39], which will be detailed below.

Other studies have shown that ASD children were colonized by low level of Faecalibacterium [44] and more specifically Faecalibacterium prausnitzii. This bacterial type could be involved in the production of anti-inflammatory cytokines such as IL-10 and IL-12. Moreover, F. prausnitzii could produce butyrate which could increase mucin production and reduce the permeability of epithelial gut barrier [45,46]. A correlation seems to exist between the relative abundance of some bacterial genera, as Flavinofractor, Acinetobacter or Ruminococcus, and the presence or absence of some ASD symptoms in childhood [39].

Pathways Linking Gut Microbiota and Development of Autism Spectrum Disorders Symptoms

The gut-brain-axis

There is a bidirectional communication between the GM and the brain, notably via the vagus nerve, which enables the transmission of information via neurotransmitter molecules such as serotonin. There is another pathway named hypothalamic-pituitary-adrenal (HPA) system, which communicates via the bloodstream with entero-endocrine molecules. The third known pathway is the immune system with pro- or anti-inflammatory cytokines that could impact brain functions [47,48]. The microbiota also produces certain fatty acids or amino acids with neuroprotective properties (Fig. 1). When GD is present, these pathways may be impacted, notably by amount variations of factors involved in these pathways.

Inflammatory cytokines and neuroinflammation

One mechanism which is particularly suspected in ASD is neuroinflammation [49]. This mechanism could lead to synaptic dysfunction, failure of microglia maturation or some other negative impacts on the brain functions [50]. One hypothesis is that neurological symptoms similar to those found in ASD children could elicit increased intestinal permeability and neuroinflammation via cytokines. The increased intestinal permeability could improve the passage of some inflammatory cytokines, and have an impact on a cerebral inflammatory reaction [47,51].

Significant levels of inflammatory cytokines were found in the blood and brain of ASD children [51]. The bacterial phyla most frequently associated with higher inflammatory cytokine levels in ASD children are Prevotella, Bacteroidetes and Bifidobacterium [40]. Some studies suggest that the inflammatory cytokine IL-6, whose production can be induced by GM, could increase inflam-mation and brain dysregulation, modify the integrity of the intestinal barrier and reduce the social behavior score in ASD [48]. In ASD children, there seems to be a lack of B. longum, which could help to reduce and regulate the production of IL-6. Moreover, a study has shown that LPS could increase pro-inflammatory cytokines interferon gamma, IL-6 and tumor necrosis factor alpha (TNFα) [52].

Neurotransmitters and short-chain fatty acids

Short-chain fatty acids (SCFA) can be produced by GM. Certain types of anaerobic bacteria, such as Bifidobacterium, Prevotella and Lactobacillus, are particularly involved in SCFA synthesis via dietary fibers fermentation [53]. The majority of SCFAs are produced from precursors such as propionate, acetate or butyrate [49]. This last one is produced specifically by Faecalibacterium which is found in GM [43]. Because of GD in ASD children, SCFA and butyrate production by Faecalibacterium could be deficient in these children [43,47]. As they could cross the blood-brain barrier, SCFA could have a neuroprotective role and anti-inflammatory properties. Thus, they could reduce neuroinflammation [49]. GM metabolizes some essential amino acids such as tryptophan, which is the precursor of serotonin (5-hydroxytryptamine [5-HT]), a neurotransmitter that plays a role in mood. Serotonin depletion could be at the root of sad or depressed moods, or of cognitive disorders [54]. These symptoms are common in ASD children. Tryptophan is also a precursor for the synthesis of other metabolites, such as 5-methoxytryptophol, which may play a protective role against the genesis of ASD in utero [55]. In addition, certain bacterial strains as Lactobacillus or Bifidobacterium could modulate the production of other neurotransmitters such as GABA [7,56], which is the main excitatory neurotransmitter in fetuses, whereas it becomes inhibitory in adults [57]. An imbalance between neuronal inhibition and excitation via the neurotransmitters GABA or glutamate could be a significant element in the mechanisms of ASD [58]. This imbalance could lead to abnormalities in cerebral information processing and behavioral alterations, and thus different perception of environment [57,58]. Several studies suggest that GABA may be deficient in the brains of ASD children, although others show equivalent levels of this neurotransmitter in all children [58,59].

Hypothalamic-pituitary-adrenal axis

It appears that HPA hyperactivity is correlated with increased corticotropic hormone levels and stress, as well as a tendency to depression in mice with sterile microbiota. However, Bifidobacterium infantis may reduce this hyperactivity in SPF mice. To date, many mechanisms remain unclear [44]. In ASD children, the HPA hyperactivity with high level of cortisol in blood is also modulated by adrenocorticotropic hormone in hypothalamus [60].

Effects of Gut Microbial-based Treatments in Autism Spectrum Disorders Children

Pre- and pro-biotics

Prebiotics are non-digestible components of the human body that benefit the health of the host by selectively stimulating the growth and activity of intestinal bacteria [61]. By contrast, probiotics are living microorganisms which, when ingested or applied topically in sufficient quantities, can correct dysbiosis. Strains of Bifidobacterium and Lactobacillus, as well as Saccharomyces boulardii, are commonly used as probiotics [61].

A double-blind study has shown for the first time the concomitant benefit of an exclusion diet combined with 6-week treatment with the prebiotic galacto-oligosaccharide immuno B-GOS (Clasado Biosciences) (Table 1) [62]. The latter could stimulate butyrate production and modulate intestinal bacterial populations. The exclusion diets used were casein-free or gluten-free. Administration of B-GOS for 6 weeks in combination with an exclusion diet significantly increased GM diversity, with an increase in Bifidobacterium spp. The study showed a trend towards a reduction in gastrointestinal disorders, although the results were not significant under the same conditions. There was also a significant improvement in the anti-sociality scores used to assess neurological criteria in ASD [62]. The study also showed an increase in Bifidobacterium spp., Ruminococcus spp., and the Lachnospiraceae when B-GOS was administered for 6 weeks without a restrictive diet. GM diversity was also increased, with no significant difference compared to no prebiotic administration [62].

Among the prebiotics, omega-3 polyunsaturated fatty acids (n-3 PUFAs) have been suggested as a potential treatment for several neurodevelopmental disorders [63]. A meta-analysis showed that n-3 PUFAs, compared with placebo, improved social interaction and repetitive and restricted interests and behaviors [64]. However, the findings cannot be generalized to all children with ASD because the included children were of different age groups (< 8 years old to 28 years old), displaying different symptom severity or high hyperactivity level and predominantly comprised males [64].

A study which included 35 ASD and 25 control patients, 3 to 25 years old, investigated the impact of the association of probiotic (Lactobacillus plantarum) and oxytocin. With association of probiotic and oxytocin, there was behavioral improvements and remodulation of GM with increasing of Ruminococcacaeae and Lachnospiraceae. On the contrary, these results were not significant on all studied aspects when oxytocin or the probiotic were administered alone (Table 1) [65].

Other randomized controlled trials have shown that administration of VISBIOME (ExeGi Pharma) probiotics, based on Lactobacillus and Bifidobacterium, improves gastrointestinal disorders associated with ASD (Table 1) [66,67]. Another study showed that concomitant administration of Bifidobacterium infantis with bovine colostrum product improved gastrointestinal disorders and certain behavioral aspects, notably with an improvement in the Aberrant Behavior Checklist (ABC)-lethargy score, whereas other ABC-scores about behavior improvement were not significant (Table 1) [68].

Pre- and pro-biotics nevertheless have a number of limitations in the treatment of ASD. Studies produced limited efficacy evidence, due to small sample sizes, short intervention duration and different drugs used [69,70]. In addition, there was no standardized probiotic regimen, with multiple different strains and concentrations of probiotics [71].

Fecal microbiota transplantation

Prior to clinical trials, preclinical FMT trials were carried out, in particular in fragile X messenger ribonucleoprotein 1 knock-out (FMR1 KO) mice displaying autistic-like symptoms. FMT from healthy mice to FMR1 KO mice improved their behavioral symptoms and restored social preference. Furthermore, the levels of inflammatory factors (TNFα, Ionized calcium-binding adapter molecule 1) were significantly reduced in the FMR1 KO mouse brains after FMT [61]. A study in mice also showed that a critical neurodevelopmental window existed for GM remodeling, and that this remodeling contributed to social behavior improvement [72]. FMT of healthy humans in an ASD mouse model could improve autistic-like symptoms such as anxiety [61]. Open-label studies on children treated with FMT from a stool-controlled donor were published (Table 2) [29,73]. After vancomycin treatment to eliminate some of the GM already present [73], FMT was administered for 4 or 8 weeks. FMT treatment showed an improvement in gastrointestinal disorders and an increase in GM diversity thanks to the graft, notably with an increase in Prevotella and Bifidobacterium, which multiplied to reach levels equivalent to neurotypical children 2 years post graft. Results also showed the improvement of behavioral symptoms, through the evaluation of the Parent Global Impressions-III score. These results remained stable for at least 8 weeks after the end of FMT treatment, and most improvements in GI symptoms were maintained after two years (Fig. 1) [73,74]. Moreover, significantly different levels of 5-HT and GABA were found in the blood of children after 4 weeks of FMT treatment, and they remained stable thereafter throughout follow-up up to 8 weeks [29]. Furthermore, in a study of 48 children separated into 2 equivalent groups, one receiving 2 FMTs every 2 months, and the other receiving rehabilitation training, behavioral symptoms studied using the Childhood Autism Rating Scale test were significantly improved compared with children who did not receive FMT. GIS improved after the first FMT, and microbiota changes were similar to those of non-ASD patients (Table 2 and Fig. 1) [75]. A case report about a 7 year-old female child with severe ASD and GIS has shown that after 5 FMT/10 weeks that GM was modified, capacity to produce SCFA by GM was improved and intestinal inflammation was improved too [76]. In addition, a retrospective study of 49 children with ASD who received a washed fecal microbiota (WMT) between June 2019 and July 2021 showed that WMT can relieve constipation and improve sleep disorders in these children without serious side effects [77].

These results look promising, but despite some randomized, controlled, double-blind trials, these studies have some limitations. Interventional placebo controlled FMT studies include a limited number of patients. A larger number of patients would be needed to confirm the results and ensure a genuine link between FMT and symptom improvement. Similarly, the patients recruited come from the same geographical region. Diversifying patients’ ethnic origins and standardizing on their age could strengthen the results obtained and erase potential confounding factors linked to an age-dependent microbiota [61]. Moreover, there are different ways to transfer microbiota as capsules or by liquid colonoscopy, and theses ways are not comparable because quantity and quality of live bacteria and localization of instillation are not similar [78,79].

Fecal transplantation is a recent treatment of patients with ASD through clinical trials. It is important to emphasize that several parameters need to be taken into account for future studies, and in particular to define a transplantation procedure (location of the transplant, better characterization of the transplant’s bacterial signature) with inclusion and exclusion criteria validated by a scientific and medical consortium, and to take into account the one-health concept, since the environment and lifestyle habits can modify the intestinal microbiota (Table 2).

CONCLUSION

The GM is impacted by a wide range of factors throughout life. Inversion of the Firmicutes/Bactoroidetes ratio, or lack of Bifidobacterium are retained elements of GD in ASD. The neuroinflammation by cytokines, decrease of SCFA, reduced 5-HT production, or imbalance between GABA and glutamate in fetuses were involved in the GD of ASD. These mechanisms could affect behavioral responses in ASD. However, GD could be modulated by administration of pre- or probiotics, such as Bifidobacterium spp. and Lactobacillus, or by FMT, which seems to improve GIS and some behavioral impairment features. Further studies with larger cohorts and standardized treatments will be needed to confirm these promising results about FMT.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Author Contributions

Conceptualization: Lisa Poupard, Zahyra Kaouah. Data acquisition: Lisa Poupard, Zahyra Kaouah. Formal analysis: Lisa Poupard, Zahyra Kaouah. Supervision: Zahyra Kaouah, Guylène Page. Writing—original draft: Lisa Poupard. Writing—review & editing: Zahyra Kaouah, Guylène Page, Vincent Thoreau.

Funding
None.
Figures
Fig. 1. Evolution of the GM throughout life and the first therapeutic promises for patients with ASD. The GM may alter the functioning of other organs, such as the brain, via the gut-brain-axis. In ASD patients, GD is observed. Microbiota-based treatments such as prebiotics, probiotics, and FMT can improve GD in ASD patients and reverse behavioral and gastro-intestinal symptoms. This figure was created with BioRender.com.
GM, gut microbiota; ASD, autism spectrum disorder; GD, gut dysbiosis; FMT, fecal microbiota transplantation; IL-17, interleukin-17.
Tables

Main clinical trials with pre- and probiotics in ASD

References Type of trials Country Number of participants Age/ gender Duration of study Treatment design Key results
Grimaldi et al. [62] (2018) Randomized double-blind UK, Denmark n = 26 4−11 yr/man and woman 10 wk 6 wk of B-GOS + exclusion diet (gluten free casein free) B-GOS + exclusion diet:
- ↗GM diversity
- ↗Bifidobacterium spp.
- Anti-sociality score improvement
B-GOS only:
- ↗Bifidobacterium spp., Ruminococcus spp., and Lachnospiraceae
Sanctuary et al. [68] (2019) Randomized double-blind (crossover) USA n = 8
ASD with GIS
2−11 yr/man and woman 12 wk - 5 wk BCP or probiotic (Bifidobacterium infantis)
- 2 wk wash-out
- 5 wk BCP + probiotic
BCP ± probiotic:
- GIS improvement
BCP only:
- ASD-related behavior mild improvement
Kong et al. [65] (2021) Randomized double-blind USA n = 35
18 ASD
17 controls
3−25 yr/man and woman 28 wk - 16 wk with probiotic (Lactobacillus plantarum) or placebo
- 12 wk with probiotic + OXT
Probiotic + OXT:
- SRS and ABC score improvement
- ↗Streptococcus Placebo + OXT:
- No significant effect on ABC or SRS score
- ↗Coprococcus-2 and Bilophila
Arnold et al. [67] (2019) Placebo-controlled (crossover) USA n = 10 ASD 3−12 yr/man and woman 19 wk - 8 wk with probiotic VISBIOME (Lactobacillus and Bifidobacterium) or placebo
- 3 wk wash-out
- 8 wk crossover treatment
GIS improvement

Arrows indicate if the parameters decrease or increase.

ASD, autism spectrum disorders; GM, gut microbiota; GIS, gastro-intestinal symptoms; BCP, bovine colostrum product; OXT, oxytocin; SRS, Social Responsiveness Scale; ABC, Aberrant Behavior Checklist.

Main clinical trials with fecal microbiota transplantation in ASD

References Type of trials Country Number of participants Age/ gender Duration of study Treatment design Key results
Kang et al. [73] (2017) Open-label USA n = 38
18 ASD
20 controls
7−16 yr man and woman 18 wk - 2 wk vancomycin
- 7/8 wk FMT treatment (oral vs. rectal route)
- 8 wk follow-up
Behavioral symptom improvement
GIS improvement
- ↗Microbiota diversity Bifidobacterium and Prevotella levels equivalent to control
Li et al. [29] (2021) Open-label China n = 56
40 ASD/GIS
16 controls
3−17 yr man and woman 12 wk - 4 wk FMT treatment (oral vs. rectal route)
- 8 wk follow-up
Behavioral symptom improvement
GIS improvement
Change of 5-HT and GABA serum levels in ASD children
Zhao et al. [75] (2019) Open-label China n = 48 ASD Not specified 12 wk 2 FMT at 2 or 4-mo intervals Behavioral symptom improvement
GIS improvement
- ↗Bacteroides fragilis and Bacteroides vulgatus
Hu et al. [76] (2023) Case report China n = 1
severe ASD/GIS
7 yr woman 12 wk - 14 days vancomycin
- 10 wk FMT
- ↗Bacteroides spp. and Ruminococcus spp.
- ↘Bifidobacterium, Streptococcus, and Faecalibacterium - ↗SCFA production
Intestinal inflammation improvement
Zhang et al. [77] (2022) Retro spective China n = 49
24 ASD/GIS
25 ASD
3−14 yr man and woman 25 mo - WMT every 4 wk between June 2019 and July 2021
- Probiotics (Bifidobacteria, Lactobacillus acidophilus, etc.) before and during WMT
Constipation relief
Sleep quality

Arrows indicate if the parameters decrease or increase.

ASD, autism spectrum disorders; FMT, fecal microbiota transplantation; GIS, gastro-intestinal symptoms; 5-HT, 5-hydroxytryptamine; GABA, gamma-aminobutyric acid; SCFA, short-chain fatty acids; WMT, washed microbiota transplantation.

References
  1. Centers for Disease Control and Prevention (CDC). Diagnostic Criteria | Autism Spectrum Disorder (ASD) | NCBDDD | CDC [Internet]. CDC; 2023 Oct 22 [cited at 2023 Oct 22]. Available from: https://www.cdc.gov/autism/index.html.
  2. Iles A. Autism spectrum disorders. Prim Care 2021;48:461-473.
    Pubmed CrossRef
  3. Wang L, Wang B, Wu C, Wang J, Sun M. Autism spectrum disorder: neurodevelopmental risk factors, biological mechanism, and precision therapy. Int J Mol Sci 2023;24:1819.
    Pubmed KoreaMed CrossRef
  4. Salari N, Rasoulpoor S, Rasoulpoor S, Shohaimi S, Jafarpour S, Abdoli N, et al. The global prevalence of autism spectrum disorder: a comprehensive systematic review and meta-analysis. Ital J Pediatr 2022;48:112.
    Pubmed KoreaMed CrossRef
  5. Lord C, Elsabbagh M, Baird G, Veenstra-Vanderweele J. Autism spectrum disorder. Lancet 2018;392:508-520.
    Pubmed KoreaMed CrossRef
  6. Fattorusso A, Di Genova L, Dell'Isola GB, Mencaroni E, Esposito S. Autism spectrum disorders and the gut microbiota. Nutrients 2019;11:521.
    Pubmed KoreaMed CrossRef
  7. Góralczyk-Bińkowska A, Szmajda-Krygier D, Kozłowska E. The microbiota-gut-brain axis in psychiatric disorders. Int J Mol Sci 2022;23:11245.
    Pubmed KoreaMed CrossRef
  8. Leader G, Abberton C, Cunningham S, Gilmartin K, Grudzien M, Higgins E, et al. Gastrointestinal symptoms in autism spectrum disorder: a systematic review. Nutrients 2022;14:1471.
    Pubmed KoreaMed CrossRef
  9. Adams JB, Johansen LJ, Powell LD, Quig D, Rubin RA. Gastrointestinal flora and gastrointestinal status in children with autism--comparisons to typical children and correlation with autism severity. BMC Gastroenterol 2011;11:22.
    Pubmed KoreaMed CrossRef
  10. Reynolds AM, Soke GN, Sabourin KR, Croen LA, Daniels JL, Fallin MD, et al. Gastrointestinal symptoms in 2- to 5-year-old children in the study to explore early development. J Autism Dev Disord 2021;51:3806-3817.
    Pubmed KoreaMed CrossRef
  11. Madra M, Ringel R, Margolis KG. Gastrointestinal issues and autism spectrum disorder. Psychiatr Clin North Am 2021;44:69-81.
    Pubmed KoreaMed CrossRef
  12. Socała K, Doboszewska U, Szopa A, Serefko A, Włodarczyk M, Zielińska A, et al. The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders. Pharmacol Res 2021;172:105840.
    Pubmed CrossRef
  13. Iglesias-Vázquez L, Van Ginkel Riba G, Arija V, Canals J. Composition of gut microbiota in children with autism spectrum disorder: a systematic review and meta-analysis. Nutrients 2020;12:792.
    Pubmed KoreaMed CrossRef
  14. Chernikova MA, Flores GD, Kilroy E, Labus JS, Mayer EA, Aziz-Zadeh L. The brain-gut-microbiome system: pathways and implications for autism spectrum disorder. Nutrients 2021;13:4497.
    Pubmed KoreaMed CrossRef
  15. Wong GC, Montgomery JM, Taylor MW. Autism spectrum disorders. In: Grabrucker AM, editor. Exon Publications;2021.
    CrossRef
  16. Vuong HE, Pronovost GN, Williams DW, Coley EJL, Siegler EL, Qiu A, et al. The maternal microbiome modulates fetal neurodevelopment in mice. Nature 2020;586:281-286.
    Pubmed KoreaMed CrossRef
  17. Lu J, Synowiec S, Lu L, Yu Y, Bretherick T, Takada S, et al. Microbiota influence the development of the brain and behaviors in C57BL/6J mice. PLoS One 2018;13:e0201829.
    Pubmed KoreaMed CrossRef
  18. Pronovost GN, Telang SS, Chen AS, Coley EJL, Vuong HE, Williams DW, et al. The maternal microbiome promotes placental development in mice. bioRxiv. [Preprint]. Available from: https://doi.org/10.1101/2023.02.15.528712.
    Pubmed KoreaMed CrossRef
  19. Benagiano M, Mancuso S, Brosens JJ, Benagiano G. Long-term consequences of placental vascular pathology on the maternal and offspring cardiovascular systems. Biomolecules 2021;11:1625.
    Pubmed KoreaMed CrossRef
  20. Choi GB, Yim YS, Wong H, Kim S, Kim H, Kim SV, et al. The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. Science 2016;351:933-939.
    Pubmed KoreaMed CrossRef
  21. Shin Yim Y, Park A, Berrios J, Lafourcade M, Pascual LM, Soares N, et al. Reversing behavioural abnormalities in mice exposed to maternal inflammation. Nature 2017;549:482-487.
    Pubmed KoreaMed CrossRef
  22. Stoner R, Chow ML, Boyle MP, Sunkin SM, Mouton PR, Roy S, et al. Patches of disorganization in the neocortex of children with autism. N Engl J Med 2014;370:1209-1219.
    Pubmed KoreaMed CrossRef
  23. Sharon G, Sampson TR, Geschwind DH, Mazmanian SK. The central nervous system and the gut microbiome. Cell 2016;167:915-932.
    Pubmed KoreaMed CrossRef
  24. Xiao L, Yan J, Yang T, Zhu J, Li T, Wei H, et al. Fecal microbiome transplantation from children with autism spectrum disorder modulates tryptophan and serotonergic synapse metabolism and induces altered behaviors in germ-free mice. mSystems 2021;6:e01343-e01320.
    Pubmed KoreaMed CrossRef
  25. Evrensel A, Ceylan ME. Fecal microbiota transplantation and its usage in neuropsychiatric disorders. Clin Psychopharmacol Neurosci 2016;14:231-237.
    Pubmed KoreaMed CrossRef
  26. Alharthi A, Alhazmi S, Alburae N, Bahieldin A. The human gut microbiome as a potential factor in autism spectrum disorder. Int J Mol Sci 2022;23:1363.
    Pubmed KoreaMed CrossRef
  27. Park SH, Lee JH, Shin J, Kim JS, Cha B, Lee S, et al. Cognitive function improvement after fecal microbiota transplantation in Alzheimer's dementia patient: a case report. Curr Med Res Opin 2021;37:1739-1744.
    CrossRef
  28. Park SH, Lee JH, Kim JS, Kim TJ, Shin J, Im JH, et al. Fecal microbiota transplantation can improve cognition in patients with cognitive decline and Clostridioides difficile infection. Aging (Albany NY) 2022;14:6449-6466.
    Pubmed KoreaMed CrossRef
  29. Li N, Chen H, Cheng Y, Xu F, Ruan G, Ying S, et al. Fecal microbiota transplantation relieves gastrointestinal and autism symptoms by improving the gut microbiota in an open-label study. Front Cell Infect Microbiol 2021;11:759435.
    Pubmed KoreaMed CrossRef
  30. Willyard C. How gut microbes could drive brain disorders. Nature 2021;590:22-25.
    Pubmed CrossRef
  31. Younge N, McCann JR, Ballard J, Plunkett C, Akhtar S, Araújo-Pérez F, et al. Fetal exposure to the maternal microbiota in humans and mice. JCI Insight 2019;4:e127806.
    Pubmed KoreaMed CrossRef
  32. González S, Selma-Royo M, Arboleya S, Martínez-Costa C, Solís G, Suárez M, et al. Levels of predominant intestinal microorganisms in 1 month-old full-term babies and weight gain during the first year of life. Nutrients 2021;13:2412.
    Pubmed KoreaMed CrossRef
  33. Raspini B, Porri D, De Giuseppe R, Chieppa M, Liso M, Cerbo RM, et al. Prenatal and postnatal determinants in shaping offspring's microbiome in the first 1000 days: study protocol and preliminary results at one month of life. Ital J Pediatr 2020;46:45.
    Pubmed KoreaMed CrossRef
  34. Bokulich NA, Chung J, Battaglia T, Henderson N, Jay M, Li H, et al. Antibiotics, birth mode, and diet shape microbiome maturation during early life. Sci Transl Med 2016;8:343ra82.
    Pubmed KoreaMed CrossRef
  35. McDonnell L, Gilkes A, Ashworth M, Rowland V, Harries TH, Armstrong D, et al. Association between antibiotics and gut microbiome dysbiosis in children: systematic review and meta-analysis. Gut Microbes 2021;13:1-18.
    Pubmed KoreaMed CrossRef
  36. Korpela K, Salonen A, Virta LJ, Kekkonen RA, Forslund K, Bork P, et al. Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children. Nat Commun 2016;7:10410.
    Pubmed KoreaMed CrossRef
  37. Galley JD, Nelson MC, Yu Z, Dowd SE, Walter J, Kumar PS, et al. Exposure to a social stressor disrupts the community structure of the colonic mucosa-associated microbiota. BMC Microbiol 2014;14:189.
    Pubmed KoreaMed CrossRef
  38. Coretti L, Paparo L, Riccio MP, Amato F, Cuomo M, Natale A, et al. Gut microbiota features in young children with autism spectrum disorders. Front Microbiol 2018;9:3146.
    Pubmed KoreaMed CrossRef
  39. Wang H, Liu S, Xie L, Wang J. Gut microbiota signature in children with autism spectrum disorder who suffered from chronic gastrointestinal symptoms. BMC Pediatr 2023;23:476.
    Pubmed KoreaMed CrossRef
  40. Morton JT, Jin DM, Mills RH, Shao Y, Rahman G, McDonald D, et al. Multi-level analysis of the gut-brain axis shows autism spectrum disorder-associated molecular and microbial profiles. Nat Neurosci 2023;26:1208-1217.
    Pubmed KoreaMed CrossRef
  41. Zuffa S, Schimmel P, Gonzalez-Santana A, Belzer C, Knol J, Bölte S, et al. Early-life differences in the gut microbiota composition and functionality of infants at elevated likelihood of developing autism spectrum disorder. Transl Psychiatry 2023;13:257.
    Pubmed KoreaMed CrossRef
  42. Jendraszak M, Gałęcka M, Kotwicka M, Regdos A, Pazgrat-Patan M, Andrusiewicz M. Commercial microbiota test revealed differences in the composition of intestinal microorganisms between children with autism spectrum disorders and neurotypical peers. Sci Rep 2021;11:24274.
    Pubmed KoreaMed CrossRef
  43. Magalhães-Guedes KT. Psychobiotic therapy: method to reinforce the immune system. Clin Psychopharmacol Neurosci 2022;20:17-25.
    Pubmed KoreaMed CrossRef
  44. Zhu S, Jiang Y, Xu K, Cui M, Ye W, Zhao G, et al. The progress of gut microbiome research related to brain disorders. J Neuroinflammation 2020;17:25.
    Pubmed KoreaMed CrossRef
  45. Dash S, Syed YA, Khan MR. Understanding the role of the gut microbiome in brain development and its association with neurodevelopmental psychiatric disorders. Front Cell Dev Biol 2022;10:880544.
    Pubmed KoreaMed CrossRef
  46. Bojović K, Ignjatović ÐI, Soković Bajić S, Vojnović Milutinović D, Tomić M, Golić N, et al. Gut microbiota dysbiosis associated with altered production of short chain fatty acids in children with neurodevelopmental disorders. Front Cell Infect Microbiol 2020;10:223.
    Pubmed KoreaMed CrossRef
  47. Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol (Lausanne) 2020;11:25.
    Pubmed KoreaMed CrossRef
  48. Saurman V, Margolis KG, Luna RA. Autism spectrum disorder as a brain-gut-microbiome axis disorder. Dig Dis Sci 2020;65:818-828.
    Pubmed KoreaMed CrossRef
  49. Yang LL, Millischer V, Rodin S, MacFabe DF, Villaescusa JC, Lavebratt C. Enteric short-chain fatty acids promote proliferation of human neural progenitor cells. J Neurochem 2020;154:635-646.
    Pubmed CrossRef
  50. Madore C, Leyrolle Q, Lacabanne C, Benmamar-Badel A, Joffre C, Nadjar A, et al. Neuroinflammation in autism: plausible role of maternal inflammation, dietary omega 3, and microbiota. Neural Plast 2016;2016:3597209.
    Pubmed KoreaMed CrossRef
  51. Downs R, Perna J, Vitelli A, Cook D, Dhurjati P. Model-based hypothesis of gut microbe populations and gut/brain barrier permeabilities in the development of regressive autism. Med Hypotheses 2014;83:649-655.
    Pubmed CrossRef
  52. Reed MD, Yim YS, Wimmer RD, Kim H, Ryu C, Welch GM, et al. IL-17a promotes sociability in mouse models of neurodevelopmental disorders. Nature 2020;577:249-253.
    Pubmed KoreaMed CrossRef
  53. Tran SM, Mohajeri MH. The role of gut bacterial metabolites in brain development, aging and disease. Nutrients 2021;13:732.
    Pubmed KoreaMed CrossRef
  54. Jenkins TA, Nguyen JC, Polglaze KE, Bertrand PP. Influence of tryptophan and serotonin on mood and cognition with a possible role of the gut-brain axis. Nutrients 2016;8:56.
    Pubmed KoreaMed CrossRef
  55. Raghavan R, Anand NS, Wang G, Hong X, Pearson C, Zuckerman B, et al. Association between cord blood metabolites in tryptophan pathway and childhood risk of autism spectrum disorder and attention-deficit hyperactivity disorder. Transl Psychiatry 2022;12:270.
    Pubmed KoreaMed CrossRef
  56. Duranti S, Ruiz L, Lugli GA, Tames H, Milani C, Mancabelli L, et al. Bifidobacterium adolescentis as a key member of the human gut microbiota in the production of GABA. Sci Rep 2020;10:14112.
    Pubmed KoreaMed CrossRef
  57. Marotta R, Risoleo MC, Messina G, Parisi L, Carotenuto M, Vetri L, et al. The neurochemistry of autism. Brain Sci 2020;10:163.
    Pubmed KoreaMed CrossRef
  58. Kolodny T, Schallmo MP, Gerdts J, Edden RAE, Bernier RA, Murray SO. Concentrations of cortical GABA and glutamate in young adults with autism spectrum disorder. Autism Res 2020;13:1111-1129.
    Pubmed KoreaMed CrossRef
  59. Gaetz W, Bloy L, Wang DJ, Port RG, Blaskey L, Levy SE, et al. GABA estimation in the brains of children on the autism spectrum: measurement precision and regional cortical variation. Neuroimage 2014;86:1-9.
    Pubmed KoreaMed CrossRef
  60. Makris G, Agorastos A, Chrousos GP, Pervanidou P. Stress system activation in children and adolescents with autism spectrum disorder. Front Neurosci 2022;15:756628.
    Pubmed KoreaMed CrossRef
  61. Liu J, Gao Z, Liu C, Liu T, Gao J, Cai Y, et al. Alteration of gut microbiota: new strategy for treating autism spectrum disorder. Front Cell Dev Biol 2022;10:792490.
    Pubmed KoreaMed CrossRef
  62. Grimaldi R, Gibson GR, Vulevic J, Giallourou N, Castro-Mejía JL, Hansen LH, et al. A prebiotic intervention study in children with autism spectrum disorders (ASDs). Microbiome 2018;6:133.
    Pubmed KoreaMed CrossRef
  63. Chang JP, Su KP. Nutritional neuroscience as mainstream of psychiatry: the evidence- based treatment guidelines for using omega-3 fatty acids as a new treatment for psychiatric disorders in children and adolescents. Clin Psychopharmacol Neurosci 2020;18:469-483.
    Pubmed KoreaMed CrossRef
  64. Mazahery H, Stonehouse W, Delshad M, Kruger MC, Conlon CA, Beck KL, et al. Relationship between long chain n-3 polyunsaturated fatty acids and autism spectrum disorder: systematic review and meta-analysis of case-control and randomised controlled trials. Nutrients 2017;9:155.
    Pubmed KoreaMed CrossRef
  65. Kong XJ, Liu J, Liu K, Koh M, Sherman H, Liu S, et al. Probiotic and oxytocin combination therapy in patients with autism spectrum disorder: a randomized, double-blinded, placebo-controlled pilot trial. Nutrients 2021;13:1552.
    Pubmed KoreaMed CrossRef
  66. Amadi CN, Orish CN, Frazzoli C, Orisakwe OE. Dietary interventions for autism spectrum disorder: an updated systematic review of human studies. Psychiatriki 2022;33:228-242.
    Pubmed CrossRef
  67. Arnold LE, Luna RA, Williams K, Chan J, Parker RA, Wu Q, et al. Probiotics for gastrointestinal symptoms and quality of life in autism: a placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 2019;29:659-669.
    Pubmed KoreaMed CrossRef
  68. Sanctuary MR, Kain JN, Chen SY, Kalanetra K, Lemay DG, Rose DR, et al. Pilot study of probiotic/colostrum supplementation on gut function in children with autism and gastrointestinal symptoms. PLoS One 2019;14:e0210064.
    Pubmed KoreaMed CrossRef
  69. He X, Liu W, Tang F, Chen X, Song G. Effects of probiotics on autism spectrum disorder in children: a systematic review and meta-analysis of clinical trials. Nutrients 2023;15:1415.
    Pubmed KoreaMed CrossRef
  70. Ng QX, Loke W, Venkatanarayanan N, Lim DY, Soh AYS, Yeo WS. A systematic review of the role of prebiotics and probiotics in autism spectrum disorders. Medicina (Kaunas) 2019;55:129.
    Pubmed KoreaMed CrossRef
  71. Feng P, Zhao S, Zhang Y, Li E. A review of probiotics in the treatment of autism spectrum disorders: perspectives from the gut-brain axis. Front Microbiol 2023;14:1123462.
    Pubmed KoreaMed CrossRef
  72. Needham BD, Tang W, Wu WL. Searching for the gut microbial contributing factors to social behavior in rodent models of autism spectrum disorder. Dev Neurobiol 2018;78:474-499.
    Pubmed CrossRef
  73. Kang DW, Adams JB, Gregory AC, Borody T, Chittick L, Fasano A, et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome 2017;5:10.
    Pubmed KoreaMed CrossRef
  74. Kang DW, Adams JB, Coleman DM, Pollard EL, Maldonado J, McDonough-Means S, et al. Long-term benefit of Microbiota Transfer Therapy on autism symptoms and gut microbiota. Sci Rep 2019;9:5821.
    Pubmed KoreaMed CrossRef
  75. Zhao H, Gao X, Xi L, Shi Y, Peng L, Wang C, et al. Mo1667 fecal microbiota transplantation for children with autism spectrum disorder. Gastrointest Endosc 2019;89(6 Suppl):AB512-AB513.
    CrossRef
  76. Hu C, He T, Zou B, Li H, Zhao J, Hu C, et al. Fecal microbiota transplantation in a child with severe ASD comorbidities of gastrointestinal dysfunctions-a case report. Front Psychiatry 2023;14:1219104.
    Pubmed KoreaMed CrossRef
  77. Zhang Y, Zhang J, Pan Z, He X. Effects of washed fecal bacteria transplantation in sleep quality, stool features and autism symptomatology: a Chinese preliminary observational study. Neuropsychiatr Dis Treat 2022;18:1165-1173.
    Pubmed KoreaMed CrossRef
  78. Chen Y, Xueying Z, Jiaqu C, Qiyi C, Huanlong Q, Ning L, et al. FTACMT study protocol: a multicentre, double-blind, randomised, placebo-controlled trial of faecal microbiota transplantation for autism spectrum disorder. BMJ Open 2022;12:e051613.
    Pubmed KoreaMed CrossRef
  79. Wei J, Chen J, Fang X, Liu T, Yuan Y, Zhang J. Protocol for the safety and efficacy of fecal microbiota transplantation liquid in children with autism spectrum disorder: a randomized controlled study. Front Microbiol 2023;14:1236904.
    Pubmed KoreaMed CrossRef


This Article

Close ✕


Cited By Articles
  • CrossRef (0)
  • Scopus (0)
  • Download (465)

Author ORCID Information

Services
Social Network Service

e-submission

Archives